Remove 2007 Remove FDA Approval Remove Pharmacy
article thumbnail

Analysis Life Sciences Thank You FDA’s nonprescription advisors find no efficacy for phenylephrine

Agency IQ

Until recently, the FDA relied on a monograph process through which firms could bring OTC drugs to market without FDA approval so long as it adhered to pre-set terms under the monograph. The FDA maintains a webpage with the full rulemaking history for OTC nasal decongestant drug products.

Science 40
article thumbnail

Medicare Coverage Analysis Worksheet

Advarra

Effective as of 2007, Medicare has offered coverage for routine costs in clinical trials. Pharmacy manual. Approval letter from the Centers for Medicare & Medicaid Services (CMS), including investigational device exemption (IDE) devices. Optional Documents. Clinical trial agreement. Lab manual. Investigator brochure (IB).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

NPP, DCC, And FDA-Regulated Medical Products

Drug & Device Law

A hundred years later, we detailed three rounds of litigation over Massachusetts’ serial efforts to ban, or at least substantially limit, the use of FDA-approved pain medications. For instance, Sorsaia primarily involves a challenge to a state trying to prevent in-state use of an FDA-approved drug for its FDA-approved use.

article thumbnail

Mifepristone Manufacturer Wins First Round in West Virginia

Drug & Device Law

The core premise of Bexis’ article is very simple: Once the FDA has said “yes” and approved a particular drug for a particular indication (“intended use”) for sale in the United States, federal preemption precludes any state from saying say “no” and trying to ban that same FDA-approved drug. In GenBioPro, Inc.

article thumbnail

The FDA and Feasible Alternative Designs

Drug & Device Law

But in prescription medical product liability litigation, products must receive FDA approval, clearance or other authorization (hereafter, collectively referred to as “approval” for short) before they can be marketed. to determine whether a proposed alternative drug would have received FDA approval.” at 237-38.

FDA 59
article thumbnail

Dobbs Would Likely Have Significant Impacts On Drug And Device Companies

Drug & Device Law

Even with some attempt to “stay in our lane,” we can see significant impacts on the legal framework in which a number of medical product manufacturers, to say nothing of distributors, pharmacies, and healthcare providers, operate. 124 (2007), which would also be knocked out by Dobbs if it sticks. Hiedeman, 694 F.3d 3d 1004 (9th Cir.